# **Product** Data Sheet

### **MMP-9-IN-3**

Molecular Weight:

Cat. No.: HY-146216

CAS No.: 2581824-48-6

Molecular Formula: C<sub>29</sub>H<sub>25</sub>N<sub>3</sub>O<sub>4</sub>

Target: MMP; Akt; Apoptosis

Pathway: Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

479.53

### **BIOLOGICAL ACTIVITY**

**Description** MMP-9-IN-3 is a MMP-9 inhibitor (IC<sub>50</sub>: 5.56 nM) that forms hydrogen bond with MMP-9. MMP-9-IN-3 also inhibits AKT activity

(IC<sub>50</sub>: 2.11 nM). MMP-9-IN-3 shows cell cytotoxicity and induces cell apoptosis. MMP-9-IN-3 can be used in the research of

 $cancers^{[1]}$ .

IC<sub>50</sub> & Target MMP-9 MMP-1 MMP-2 MMP13

5.56 nM (IC<sub>50</sub>) 447 nM (IC<sub>50</sub>) 221 nM (IC<sub>50</sub>) 295 nM (IC<sub>50</sub>)

 $\mathsf{AKT}$ 

2.11 nM (IC<sub>50</sub>)

In Vitro MMP-9-IN-3 (compound 28, 0-1 μM approximately, 72 h) shows cytotoxicity to Wi-38, MCF-7, NFS-60, HepG-2 cells<sup>[1]</sup>.

MMP-9-IN-3 (72 h) induces apoptosis in MCF-7, NFS-60 and HepG-2 cells at 6.6 nM, 5.8 nM, 5.7 nM respectively<sup>[1]</sup>.

MMP-9-IN-3 (72 h) induces significant caspase 3/7 activation in MCF-7, NFS-60 and HepG-2 cells at 6.6 nM, 5.8 nM, 5.7 nM

respectively<sup>[1]</sup>.

MMP-9-IN-3 (5.7 nM, 24 h) inhibits cell migration in HepG-2 cells<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay<sup>[1]</sup>

Cell Line:	Wi-38, MCF-7, NFS-60, HepG-2 cells	
Concentration:	0-1 μM approximately	
Incubation Time:	72 h	
Result:	Showed cytotoxicity with IC $_{50}$ : 314 nM (Wi-38), 6.6 nM (MCF-7), 5.8 nM (NFS-60), 5.7 nM (HepG-2).	

## Cell Migration Assay [1]

Cell Line:	HepG-2
Concentration:	5.7 nM
Incubation Time:	24 h

Result:	Inhibited cell migration by 71.25%.

### **REFERENCES**

[1]. Mohammed Salah Ayoup, et al. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis. Eur J Med Chem. 2020 Jan 15;186:111875.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech @ Med Chem Express.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA